- Home
- TRDA vs STK Comparison
TRDA vs STK Comparison
Compare TRDA & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- STK
- Stock Information
- Founded
- TRDA 2016
- STK 2009
- Country
- TRDA United States
- STK United States
- Employees
- TRDA N/A
- STK N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- TRDA Health Care
- STK Finance
- Exchange
- TRDA Nasdaq
- STK Nasdaq
- Market Cap
- TRDA 609.7M
- STK 553.2M
- IPO Year
- TRDA 2021
- STK N/A
- Fundamental
- Price
- TRDA $17.85
- STK $33.14
- Analyst Decision
- TRDA Strong Buy
- STK
- Analyst Count
- TRDA 3
- STK 0
- Target Price
- TRDA $23.33
- STK N/A
- AVG Volume (30 Days)
- TRDA 132.5K
- STK 38.2K
- Earning Date
- TRDA 11-05-2024
- STK 01-01-0001
- Dividend Yield
- TRDA N/A
- STK 6.60%
- EPS Growth
- TRDA N/A
- STK N/A
- EPS
- TRDA 1.55
- STK N/A
- Revenue
- TRDA $215,232,000.00
- STK N/A
- Revenue This Year
- TRDA $47.63
- STK N/A
- Revenue Next Year
- TRDA N/A
- STK N/A
- P/E Ratio
- TRDA $11.51
- STK N/A
- Revenue Growth
- TRDA 146.92
- STK N/A
- 52 Week Low
- TRDA $10.75
- STK $24.95
- 52 Week High
- TRDA $20.49
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- TRDA 48.42
- STK 48.64
- Support Level
- TRDA $19.28
- STK $33.45
- Resistance Level
- TRDA $20.49
- STK $33.95
- Average True Range (ATR)
- TRDA 0.92
- STK 0.45
- MACD
- TRDA -0.01
- STK 0.01
- Stochastic Oscillator
- TRDA 25.21
- STK 51.43
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.